Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$89.3 million.

  • Taysha Gene Therapies' Net Income towards Common Stockholders fell 28.24% to -$32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 338.82%. This contributed to the annual value of -$89.3 million for FY2024, which is 19.96% up from last year.
  • As of FY2024, Taysha Gene Therapies' Net Income towards Common Stockholders stood at -$89.3 million, which was up 19.96% from -$111.6 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Net Income towards Common Stockholders peaked at -$60.0 million during FY2020, and registered a low of -$174.5 million during FY2021.
  • In the last 3 years, Taysha Gene Therapies' Net Income towards Common Stockholders had a median value of -$111.6 million in 2023 and averaged -$122.3 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Net Income towards Common Stockholders tumbled by 190.82% in 2021 and then surged by 32.80% in 2023.
  • Over the past 5 years, Taysha Gene Therapies' Net Income towards Common Stockholders (Yearly) stood at -$60.0 million in 2020, then crashed by 190.82% to -$174.5 million in 2021, then rose by 4.88% to -$166.0 million in 2022, then spiked by 32.80% to -$111.6 million in 2023, then climbed by 19.96% to -$89.3 million in 2024.